[Edaily Reporter PARK MIN ] #CMES Robotics soared to the daily price limit on the 30th after announcing a “Physical AI partnership” with NCsoftCorporation(036570).
According to MP Doctor, as of 8:25 a.m. that day, CMES Robotics was trading at the daily price limit of 18,440 won—a 29.95% increase—on the pre-market alternative exchange (NXT). Lee Yeon-soo, CEO of NC AI (left), and Lee Seong-ho, CEO of CMES Robotics (right), pose for a commemorative photo. (Photo courtesy of CMES Robotics) The company announced today that it has signed a memorandum of understanding (MOU) with NC AI, the artificial intelligence (AI) subsidiary of NCsoftCorporation(036570), for “collaboration on joint research and development based on Physical AI and mutual technology sharing.”
This agreement was initiated to combine the capabilities of CMES Robotics—which has been supplying industrial automation solutions using Physical AI-based robotics technology—with those of NC AI, which possesses core Physical AI technologies such as WorldModel.
The two companies plan to advance physical AI technology—which enables robots to independently perceive their environment, make decisions, and perform tasks in industrial settings—and jointly develop next-generation robotics solutions applicable to real-world logistics and manufacturing sites.
The companies believe this collaboration will help address the shortage of training data and the gap between simulation and reality—two major challenges in physical AI. Their vision is to create a virtuous cycle in which real-world data is used to build virtual environments and train AI models, and the trained models are then applied back to the real-world environment.
A British startup that can teach robots new skills simply by showing them a human performing a task just once has successfully secured a large-scale investment. Expectations that this technology could…
SEMPIO FOODS(248170)will merge with its holding company, SEMPIO. The plan is to streamline the holding company structure and reorganize the management structure around the operating company to enhance…
Curocell Inc.(372320)is moving to expand the second-line treatment indication for “Limkato,” Korea’s first domestically developed chimeric antigen receptor T-cell (CAR-T) therapy.Curocell Inc. announc…